OGIVRI subst sèche 440 mg c solv flac

7680674700012 CH-67470 L01FD01 07.16.1.

Reimbursement limitations:

OGIVRPERJ.01

OGIVRI en association avec le pertuzumab (PERJETA) comme traitement adjuvant du cancer du sein
Les …

OGIVRI subst sèche 440 mg c solv flac
OGIVRI subst sèche 440 mg c solv flac
OGIVRI subst sèche 440 mg c solv flac
1 / 3
google

Details

Product number
6747001
CPT
-
Packaging group
1
Unit
Durchstechflasche(n)
Composition
Praeparatio cryodesiccata: trastuzumabum 440 mg, histidinum, histidini hydrochloridum monohydricum, macrogolum 3350, sorbitolum 337.9 mg, acidum hydrochloridum, natrii hydroxidum corresp. natrium 0.18 mg, pro vitro. Solvens: alcohol benzylicus 231 mg, aqua ad iniectabile q.s. ad solutionem 20 ml, solutio reconstituta 1 ml corresp. trastuzumabum 21 mg.

Articles (1)

Ogivri 440 mg, Pulver für ein Konzentrat zur Herstellung einer Infusionslösung
Pulver für ein Konzentrat zur Herstellung einer Infusionslösung
1
View

Official Swissmedic V2 data

Additional information from the official database

Detailed composition

Substance Quantity Type Category
SOLV
231.0 MG Substance Konservierungsstoff (Conservateur)
PRC
440.0 MG Substance Wirkstoff (Principe actif)
SOLV
- Substance HNIDK
PRC
- Substance HNIDK
PRC
- Substance HNIDK
PRC
- Substance HNIDK
SOLV
21.0 MG Substance Wirkstoff (Principe actif)
PRC
337.9 MG Substance HBESI
PRC
- Substance HNIDK
PRC
- Substance HNIDK
PRC
0.18 MG Substance HBESI

Reimbursement information

Public price
CHF 1469.00
Specialties list
Yes
Generic
No

Reimbursement limitation

SL addition date: 01/09/2020

Authorization holder

Medius AG

4132 Muttenz

Authorization information

Swissmedic authorization number
67470
Drug name
Ogivri 440 mg, Pulver für ein Konzentrat zur Herstellung einer Infusionslösung
Galenic form
LSPA
ATC Code
L01FD01
Authorization status
Z
Dispensation category
A
First authorization
02/04/2020
Authorization expiration date
31/12/9999
IT number
07.16.1.
Domain
Human medicine
Field of application
Mammakarzinom, Magenkarzinom oder Karzinom des gastroösophagealen Übergangs

Packaging details

Description (FR)
OGIVRI subst sèche 440 mg c solv flac
Description (DE)
OGIVRI Trockensub 440 mg c Solv Durchstf
Market launch
02/04/2020
Narcotic (BTM)
No